Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jogc.2018.11.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinician's perceptions and experiences with tobacco treatment in people who use cannabis: a qualitative study.
Subst Abuse Treat Prev Policy
January 2025
Tobacco Control Unit, Cancer Control and Prevention Program, Institut Català d'OncologiaL'Hospitalet de Llobregat, Barcelona, Spain.
Introduction: Global demand for the treatment of cannabis use disorder has increased significantly, prompting a need to understand effective strategies for addressing concurrent cannabis and tobacco use. This study focuses on clinicians' experiences and perceptions in delivering tobacco cessation services to people who use cannabis.
Methods: Fifteen participants (12 females, 3 males) participated in three homogenous focus groups, including two groups with extensive experience in providing tobacco cessation among the substance use population in Catalonia, Spain, and one group of clinicians without such experience.
Peer-review Blinded Assay Test (P-BAT): a framework for trustless laboratory quality assurance for state-regulated cannabis markets.
J Cannabis Res
January 2025
PureVita Labs LLC, 153 James P Murphy Ind Hwy , West Warwick, 02893-2382, United States.
The purpose of laboratory testing in the cannabis industry is to ensure public safety by preventing products that exceed hazardous limits of contaminants from reaching consumers, and to provide consumers with transparent and accurate label information so that they can make informed decisions when purchasing and using products. However, cannabis testing does not exist in a vacuum of incentives-some incentives exist that are in direct conflict with what is best for consumers. For example, cultivators and distributors will prefer to use the services of laboratories that find the highest THC concentrations or lowest contaminant concentrations, regardless of the accuracy of their testing results.
View Article and Find Full Text PDFPhysicians' and patients' perceived risks of chronic pain medication and co-medications in Quebec, Canada: a cross-sectional study.
BMC Prim Care
January 2025
Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue (UQAT), Rouyn-Noranda, Québec, Canada.
Background: The risks associated with medications and co-medications for chronic pain (CP) can influence a physician's choice of drugs and dosages, as well as a patient's adherence to the medication. High-quality care requires patients to participate in medication decisions. This study aimed to compare perceived risks of medications and co-medications between physicians and persons living with CP.
View Article and Find Full Text PDFRegarding Ogunsola et al.
Cannabis Cannabinoid Res
January 2025
Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!